PD-L1 expression is a predictive biomarker for CIK cell-based immunotherapy in postoperative patients with breast cancer

Table 3 Univariate and multivariate analysis of overall survival (OS) for breast cancer patients who received adjuvant CIK cell immunotherapy

Variables	Univariate analysis			Multivariate analysis
Variables	HR	95% CI	p value	HR	95% CI	p value
Age (< 50 vs. ≥ 50)	1.031	0.670–1.231	0.747
Tumor size (< 20 vs. ≥ 20) (mm)	2.918	1.554–4.609	< 0.001*	1.895	0.881–2.805	0.493
TNM stage (I-II vs. III)	1.732	1.275–2.618	0.013*	1.787	1.271–2.991	0.015*
Histological differentiation (I-II vs. III)	1.078	0.487–1.499	0.718
Positive lymph node ratio (< 0.21 vs. ≥ 0.21)	2.004	0.812–2.260	0.083
ER (pos vs. neg)	0.714	0.513–1.919	0.057
PR (pos vs. neg)	0.721	0.486–1.542	0.501
Herb2 (pos vs. neg)	1.405	1.207–2.711	0.029*	1.193	0.814–2.569	0.807
PD-L1 expression (pos vs. neg)	0.610	0.352–0.903	< 0.001*	0.569	0.318–0.830	< 0.001*
TNBC (yes vs. no)	1.902	0.890–2.925	0.604